Area of research
Hepatology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Gastric Cancer Management and Outcomes, Colorectal Cancer Treatments and Studies, and Cancer, Hypoxia, and Metabolism.
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment
China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition)
Lactate modulates the function of myeloid-derived suppressor cells via Ten-Eleven-Translocation-2-mediated demethylation of glucocorticoid-inducible kinase 1 in lung cancer model
Boosting confidence in class-incremental learning via discriminative local feature enhancement
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Evaluation of belimumab in treatment of Chinese childhood-onset systemic lupus erythematosus: a prospective analysis from a multicentre study
ORIENT-32: Updated characterization of response to sintilimab plus bevacizumab biosimilar (IBI305) vs sorafenib for unresectable hepatocellular carcinoma.
Report of adverse events of special interest (AESIs) for sintilimab plus a bevacizumab biosimilar (IBI305) in unresectable hepatocellular carcinoma.
Abstract CT150: Result of an open-label phase 2 trial of dual TORC1/TORC2 inhibitor onatasertib (ATG-008) in HBV+ advanced hepatocellular carcinoma (HCC) subjects who have received at least one prior line of systemic therapy (TORCH)
Dendrimer-based drug delivery systems: history, challenges, and latest developments
Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition)
KAT2A/E2F1 Promotes Cell Proliferation and Migration via Upregulating the Expression of UBE2C in Pan-Cancer
PRR11 promotes cell proliferation by regulating PTTG1 through interacting with E2F1 transcription factor in pan-cancer
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
Efficacy, Safety, and Immunogenicity of HLX04Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatmentfor Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase IIIStudy
Vitamin A deficiency increases the risk of gastrointestinal comorbidity and exacerbates core symptoms in children with autism spectrum disorder
Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.
FATS regulates polyamine biosynthesis by promoting ODC degradation in an ERβ-dependent manner in non-small-cell lung cancer
Cost‐effectiveness analysis of cabozantinib as second‐line therapy in advanced hepatocellular carcinoma
Atherogenic index of plasma is a novel predictor of non-alcoholic fatty liver disease in obese participants: a cross-sectional study
A multicenter phase II study of donafenib in patients with advanced hepatocellular carcinoma.